Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.
You may also be interested in...
Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals
Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.
Deals Of The Week: Pfizer Goes For An IPO
Pfizer’s strategy is to monetize part of its animal health division while continuing new CEO Ian Read’s increased focus on biopharmaceuticals.
Post Biocon, Pfizer Pushes Forward On Biosimilar MABs
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.